NCT00404573已完成2 期
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia
Forest Laboratories2 个研究点 分布在 1 个国家目标入组 375 人开始时间: 2006年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 375
- 试验地点
- 2
- 主要终点
- PANSS Total Score
研究概览
简要总结
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of the three treatment groups--one of two doses of RGH-188 or placebo
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female inpatients, 18-65 years of age, meeting DSM-IV-TR criteria for schizophrenia and having a Total Positive and Negative Syndrome Scale (PANSS) Score >=80 and <=
- •A score >=4 on item P1 (delusions) or P3 (hallucinatory behavior) and a score of >=4 on item P2 (conceptual disorganization) or P6 (suspiciousness/persecution) of the PNASS
排除标准
- •Patients with documented disease of the central nervous system that can interfere with the trial assessments, including but not limited to stroke, tumor, Parkinson's, organic brain disease, seizure disorder (except for febrile convulsions during infancy), chronic infection, or neurosyphilis; or patients who have suffered a traumatic brain injury resulting in significant impairment
结局指标
主要结局
PANSS Total Score
次要结局
- CGI-S
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute ManiaBipolar DisorderNCT00488618Forest Laboratories238
已完成
2 期
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive DisorderMajor Depressive DisorderNCT00854100Forest Laboratories231
已完成
2 期
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisModerate to Severe Atopic DermatitisNCT05549947Shanghai Hengrui Pharmaceutical Co., Ltd.158
已完成
3 期
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisModerate to Severe Atopic DermatitisNCT06468956Guangdong Hengrui Pharmaceutical Co., Ltd652
招募中
2 期
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo NodularisPrurigo NodularisNCT06554509Guangdong Hengrui Pharmaceutical Co., Ltd423